GLPwatch
Papers (10401)
Page 30 of 174, ranked by citation count.
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.
- Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1α/CXC chemokine receptor 4 pathway.
- Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
- The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.
- Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
- Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
- Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus.
- APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
- As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.
- Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
- A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.
- Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.
- Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
- The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.
- A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
- Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
- Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis.
- The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
- Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
- Effect of Liraglutide on Arterial Inflammation Assessed as [<sup>18</sup>F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
- Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.
- The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.
- Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
- A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.
- GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
- One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
- Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
- No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
- Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
- GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.
- Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
- Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
- Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
- Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
- Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast.
- GLP-1R agonist therapy for diabetes: benefits and potential risks.
- Exenatide and weight loss.
- Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.
- Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
- Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.
- Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
- Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.
- Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.
- Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.
- A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction.
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
- Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.
- Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.
- Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway.
- Exendin-4 protects hypoxic islets from oxidative stress and improves islet transplantation outcome.
- A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
- Alzheimer's disease and diabetes: new insights and unifying therapies.
- Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review.
- Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
- The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.